



Sheet 1 of 1

TO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(Use several sheets if necessary)		APPLICANT: Harry R. Davis	
				FILING DATE: 01/25/2002	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

M&	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
M&	AL WO 95/35277	12/28/95	PCT	C07D	205/08		
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M&	AQ	Thompson, G.R. et al., "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782 abstract; figure 8
M&	AR	Kosoglou, T. et al., "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP1132089 abstract
	AS	
	AT	
	AU	
	AV	

EXAMINER	DATE CONSIDERED
<i>MJL</i>	10/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.